Sol-Gel Technologies (SLGL) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($248.4 million vs $230.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLGL | VCRE |
|---|---|---|
| Share price | $70.34 | $8.82 |
| Market cap | $230.29M | $248.41M |
| 1-day change | -2.23% | +1.85% |
| YTD return | +66.92% | — |
| 1-year return | +78.89% | — |
| 5-year return | -24.57% | — |
| EPS (TTM) | $-5.43 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.97 | $17.80 |
| 52-week low | $28.81 | $7.88 |
| Distance from 52-week high | -28.20% | -50.45% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +116.80% | +275.96% |
| Average volume | 55.55K | 16.22K |
| Shares outstanding | 3.27M | 28.16M |
| Employees | 28 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
SLGL vs VCRE FAQ
Which is bigger, Sol-Gel Technologies or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $248.41M compared with $230.29M for Sol-Gel Technologies (SLGL).
Are Sol-Gel Technologies and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.